JSE Equity Intelligence Report

Aspen Pharmacare Holdings Ltd (APN:SJ)

Generated: November 22, 2026
Healthcare & Pharmaceuticals
South Africa
Institutional Feed
Verified
Valuation & Metrics
178.15 ZAR
YTD Performance: +57.06%
28D Momentum: +11.90%
Regression Slope: 0.9
7D Projection: 184.46
7D Expected Range: 172.91 - 196.01
Signal Reliability: 90%
Based on data alignment, market sentiment and historical volatility
Executive Summary
  • Aspen Pharmacare shows strong 28-day momentum (+12.5%), signaling renewed investor confidence in SA healthcare despite macro headwinds.
  • As a domestic-focused pharma player, Aspen benefits from stable local demand but faces ZAR weakness risk—currency depreciation raises import costs for active ingredients.
  • No recent news detected; momentum appears technical. Monitor SARB rate decisions and Rand stability—higher rates support currency but may pressure consumer healthcare spending.
Strong Outlook
Price Performance (28-Day Trend)
Intelligence Matrix
🚢 Logistics & Supply

SA pharma supply chains depend on stable port throughput (Transnet) and reliable power for cold-chain storage; Eskom load-shedding remains a latent cost pressure on distribution networks.

🌍 Origin Insight

Aspen is SA-headquartered with significant domestic revenue exposure; limited USD earnings hedge compared to mining peers. Rand depreciation increases imported API costs, compressing margins unless pricing power holds.

⚖️ Regulatory Shift

SA healthcare pricing remains regulated; SAHPRA approval timelines and NHI policy evolution could reshape market access and reimbursement—monitor government health spending commitments.

📊 Price Trend

28-day bullish expansion (+12.5%) reflects steady upward accumulation; no major volatility spikes detected. Trajectory remains constructive absent negative news catalyst; support levels warrant monitoring if sentiment shifts.